Literature DB >> 19825454

Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.

Dario Campana1.   

Abstract

Assays that measure minimal residual disease (MRD) can determine the response to treatment in patients with acute lymphoblastic leukemia (ALL) much more precisely than morphologic screening of bone marrow smears. The clinical significance of MRD, detected by flow cytometry or polymerase chain reaction-based methods in childhood ALL, has been established. Hence, MRD is being used in several clinical trials to adjust treatment intensity. Similar findings have been gathered in adult patients with ALL, making MRD one of the most powerful and informative parameters to guide clinical management. This article discusses practical issues related to MRD methodologies and the evidence supporting the use of MRD for risk assignment in clinical trials.

Entities:  

Mesh：

Year:  2009        PMID： 19825454      PMCID： PMC2762949          DOI： 10.1016/j.hoc.2009.07.010

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  93 in total

1.  Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

Authors:  Renato Bassan; Orietta Spinelli; Elena Oldani; Tamara Intermesoli; Manuela Tosi; Barbara Peruta; Giuseppe Rossi; Erika Borlenghi; Enrico M Pogliani; Elisabetta Terruzzi; Pietro Fabris; Vincenzo Cassibba; Giorgio Lambertenghi-Deliliers; Agostino Cortelezzi; Alberto Bosi; Giacomo Gianfaldoni; Fabio Ciceri; Massimo Bernardi; Andrea Gallamini; Daniele Mattei; Eros Di Bona; Claudio Romani; Anna Maria Scattolin; Tiziano Barbui; Alessandro Rambaldi
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

2.  Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.

Authors:  Jun J Yang; Cheng Cheng; Wenjian Yang; Deqing Pei; Xueyuan Cao; Yiping Fan; Stanley B Pounds; Geoffrey Neale; Lisa R Treviño; Deborah French; Dario Campana; James R Downing; William E Evans; Ching-Hon Pui; Meenakshi Devidas; W P Bowman; Bruce M Camitta; Cheryl L Willman; Stella M Davies; Michael J Borowitz; William L Carroll; Stephen P Hunger; Mary V Relling
Journal:  JAMA       Date:  2009-01-28       Impact factor: 56.272

Review 3.  Molecular determinants of treatment response in acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

4.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

5.  Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.

Authors:  Andishe Attarbaschi; Georg Mann; Renate Panzer-Grümayer; Silja Röttgers; Manuel Steiner; Margit König; Eva Csinady; Michael N Dworzak; Markus Seidel; Dasa Janousek; Anja Möricke; Carsten Reichelt; Jochen Harbott; Martin Schrappe; Helmut Gadner; Oskar A Haas
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

7.  Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.

Authors:  V H J Van der Velden; L Corral; M G Valsecchi; M W J C Jansen; P De Lorenzo; G Cazzaniga; E R Panzer-Grümayer; M Schrappe; A Schrauder; C Meyer; R Marschalek; L L Nigro; M Metzler; G Basso; G Mann; M L Den Boer; A Biondi; R Pieters; J J M Van Dongen
Journal:  Leukemia       Date:  2009-02-12       Impact factor: 11.528

Review 8.  Minimal residual disease in acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

9.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Xiaoping Su; Jinghui Zhang; Ina Radtke; Letha A A Phillips; Christopher B Miller; Jing Ma; Wei Liu; Cheng Cheng; Brenda A Schulman; Richard C Harvey; I-Ming Chen; Robert J Clifford; William L Carroll; Gregory Reaman; W Paul Bowman; Meenakshi Devidas; Daniela S Gerhard; Wenjian Yang; Mary V Relling; Sheila A Shurtleff; Dario Campana; Michael J Borowitz; Ching-Hon Pui; Malcolm Smith; Stephen P Hunger; Cheryl L Willman; James R Downing
Journal:  N Engl J Med       Date:  2009-01-07       Impact factor: 91.245

10.  Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.

Authors:  M Paganin; M Zecca; G Fabbri; K Polato; A Biondi; C Rizzari; F Locatelli; G Basso
Journal:  Leukemia       Date:  2008-08-28       Impact factor: 11.528
View more
  27 in total

1.  New markers for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Christopher Clark; Laura Key; Peixin Liu; Mohammad Mehrpooya; Patricia Stow; Xiaoping Su; Sheila Shurtleff; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

2.  Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing.

Authors:  Stan Pounds; Xueyuan Cao; Cheng Cheng; Jun J Yang; Dario Campana; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Int J Data Min Bioinform       Date:  2011       Impact factor: 0.667

3.  Value of multifaced approach diagnosis and classification of acute leukemias.

Authors:  Silvana Angelescu; Nicoleta Mariana Berbec; Andrei Colita; Doina Barbu; Anca Roxana Lupu
Journal:  Maedica (Buchar)       Date:  2012-09

4.  Flow Cytometry Based MRD and Its Impact on Survival Outcome in Children and Young Adults with ALL: A Prospective Study from a Tertiary Cancer Centre in Southern India.

Authors:  Soumya Surath Panda; Venkatraman Radhakrishnan; Prasanth Ganesan; Rejiv Rajendranath; Trivadi S Ganesan; Kamalalayan Raghavan Rajalekshmy; Rajesh Kumar Bhola; Hemlata Das; Tenali Gnana Sagar
Journal:  Indian J Hematol Blood Transfus       Date:  2019-11-09       Impact factor: 0.900

5.  Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival.

Authors:  Veronika Bachanova; Michael J Burke; Sophia Yohe; Qing Cao; Karamjeet Sandhu; Timothy P Singleton; Claudio G Brunstein; John E Wagner; Michael R Verneris; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-16       Impact factor: 5.742

Review 6.  Recent advances in hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia.

Authors:  Veronica Jude; Ka Wah Chan
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

7.  Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.

Authors:  Misato Kikuchi; Junji Tanaka; Takeshi Kondo; Satoshi Hashino; Masaharu Kasai; Mitsutoshi Kurosawa; Hiroshi Iwasaki; Masanobu Morioka; Tsugumichi Kawamura; Nobuo Masauzi; Takashi Fukuhara; Yasutaka Kakinoki; Hajime Kobayashi; Satoshi Noto; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2010-09-10       Impact factor: 2.490

Review 8.  Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.

Authors:  Elaine Coustan-Smith; Dario Campana
Journal:  Best Pract Res Clin Haematol       Date:  2010-10-28       Impact factor: 3.020

9.  Flow cytometric detection of the classical hodgkin lymphoma: clinical and research applications.

Authors:  Mikhail Roshal; Brent L Wood; Jonathan R Fromm
Journal:  Adv Hematol       Date:  2010-11-28

Review 10.  Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.